ABBOTT LABORATORIES (ABT) Stock Price, Financials & Summary

Price chart

Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30

Key dataOct 30, 2026

Open$106.15

From 52W high−18.65%

Volume8.38M

Market cap$183.84B

P/E (TTM)39.3x

P/S (TTM)3.8x

Div yield2.37%

Key dataOct 30, 2026

Open

$106.15

From 52W high

−18.65%

Volume

8.38M

Market cap

$183.84B

ValuationView details →

P/E (Fwd)

18.2x

EV/EBITDA

—

P/E (TTM)

39.3x

RSI (14)

60.0

MomentumView details →

1D Return

+1.60%

YTD Return

−15.07%

SummaryUpdated Sep 1, 2026

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company founded in 1888 and headquartered in North Chicago, Illinois. Originally established as a pharmaceutical company by Dr. Wallace Calvin Abbott, the company has evolved over more than 135 years into one of the world's largest healthcare corporations. Abbott operates across four major business segments: Medical Devices, Diagnostics, Nutritional Products, and Established Pharmaceutical Products, serving patients and healthcare providers in over 160 countries worldwide.

Ask drillr about ABBOTT LABORATORIES →

ValuationView details →

P/E (Fwd)

18.2x

P/E (TTM)

39.3x

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

3.8x

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

57.12%

Net Margin

9.75%

EBITDA Margin

20.13%

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

+10.00%

EPS YoY

−66.45%

FCF YoY

+6.91%

Revenue CAGR 3Y

+0.51%

EPS CAGR 3Y

−1.72%

EBITDA YoY

−17.69%

MomentumView details →

1D Return

+1.60%

YTD Return

−15.07%

1Y Return

−13.92%

RSI (14)

60.0

vs 50D SMA

+1.98%

vs 200D SMA

+4.63%

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

2.37%

Div Rate

$2.52

Div Growth 1Y

+6.78%

EarningsView details →

EPS (Actual)

$1.42

EPS Surprise

0.00%

Beats (12Q)

4/12

Next Q EPS Est

$1.64

Avg Surprise (4Q)

0.74%

Rev Surprise

0.45%

Financials snapshotView financials →

Revenue (TTM)

48.23B

Net Income (TTM)

4.70B

Op. CF (TTM)

—

Next earningsJan 28, 2027 →

Latest newsMore news →

ABBOTT LABORATORIES announced strong 30-day results from its TECTONIC study evaluating the investigational SonicForce Coronary IVL System.10h ago

ABBOTT LABORATORIES announced that it initiated the CROWN-MV pivotal trial to evaluate the safety and effectiveness of its investigational Cephea Mitral Valve System for symptomatic mitral valve disease patients who are not candidates for surgery or transcatheter repair.4d ago

Similar companies

Sky Labs Inc.386380.KQ T&L Co., Ltd.340570.KQ Vieworks Co., Ltd.100120.KQ Value Added Technology Co., Ltd.043150.KQ Shinhung Co., Ltd004080.KS Medtronic plcMDT Find similar companies →

Latest newsMore news →

ABBOTT LABORATORIES announced strong 30-day results from its TECTONIC study evaluating the investigational SonicForce Coronary IVL System.10h ago ABBOTT LABORATORIES announced that it initiated the CROWN-MV pivotal trial to evaluate the safety and effectiveness of its investigational Cephea Mitral Valve System for symptomatic mitral valve disease patients who are not candidates for surgery or transcatheter repair.4d ago